目的 探讨多西他赛密集新辅助化疗治疗乳腺癌患者的临床疗效.方法 对87例乳腺癌患者均予以多西他赛密集新辅助化疗,根据免疫组化法检测结果 对其进行分子分型,分为三阴性组(19例)、人表皮生长因子受体过表达组(21例)、Luminal A组(23例)、Luminal B组(24例).比较4组患者的临床疗效及随访1 a无病生存率.结果 三阴性组、人表皮生长因子受体过表达组临床有效率分别为84.21％和80.95％,两组比较差异无统计学意义(P＞0.05);Luminal A组、Luminal B组临床有效率分别为60.87％和62.50％,两组比较差异无统计学意义(P＞0.05);三阴性组总有效率均显著高于Luminal A组和Luminal B组(P＜0.01).随访1 a, Luminal A组、Luminal B组无病生存率均显著高于三阴性组和人表皮生长因子受体过表达组(P＜0.05),且Luminal A组无病生存率最高,三阴性组无病生存率最低.结论 多西他赛密集新辅助化疗治疗不同分子分型乳腺癌患者临床疗效和预后效果均存在一定差异,因此应根据分子分型预测患者预后效果.“,”Objective To analyze the curative effect of docetaxel-intensive neoadjuvant chemotherapy in the treatment of breast cancer. Methods 87 cases with breast cancer were all given docetaxel-intensive neoadjuvant chemotherapy and divided into the triple-negative group (19 cases),HER-2 overexpression group (21 cases), Luminal A group (23 cases) and Luminal B group (24 cases) according to the molecular classification by IHC. The clinical effect and 1 year follow up DFS among the four groups were compared. Results The clinical effective rates of the triple-negative group, HER-2 overexpression group were 84.21 ％, 80. 95％,the difference between the two groups was not statistic significant (P ＞0.05); the clinical effective rates of the Luminal A group and Luminal B group were 60.87％,62.50％,the difference between the two groups was not statistic significant (P＞0.05); the total effective rate of the triple-negative group was significantly higher than that of the Luminal A group and Luminal B group (P＜0.01). After 1 year follow up, the DFS of Luminal A group and Luminal B group were significantly higher than those of the triple-negative group, HER-2 overexpression group (P＜0.05),and Luminal A group had the highest DFS, the triple-negative group had the lowest DFS. Conclusion Docetaxel-intensive neoadjuvant chemotherapy in the treatment of breast cancer with different molecular classification has different clinical effect and prognosis effect, therefore,the prognosis effect of patients should be predicted based on molecular classification.